Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison T Stopeck

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2011
Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumorsDavid E Gerber, Alison T Stopeck, Lucas Wong, et al.
Breast Cancer Research and Treatment|September 16, 2022
Blood plasma derived extracellular vesicles (BEVs): particle purification liquid chromatography (PPLC) and proteomic analysis reveals BEVs as a potential minimally invasive tool for predicting response to breast cancer treatmentFolnetti A Alvarez, Hussein Kaddour, Yuan Lyu, et al.
Journal of Magnetic Resonance Imaging : JMRI|August 31, 2002
Radial fast spin-echo method for T2-weighted imaging and T2 mapping of the liverMaria I Altbach, Eric K Outwater, Theodore P Trouard, et al.
Clinical & Experimental Metastasis|June 14, 2012
The role of targeted therapy and biomarkers in breast cancer treatmentAlison T Stopeck, Ursa Brown-Glaberman, Hong Yuen Wong, et al.
Blood|June 27, 2012
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2015
The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone diseaseIngo J Diel, Jean-Jacques Body, Alison T Stopeck, et al.
Leukemia & Lymphoma|April 18, 2009
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Breast Cancer Research and Treatment|January 18, 2022
Sulindac Improves Stiffness and Quality of Life in Women Taking Aromatase Inhibitors for Breast CancerJessica A Martinez, Betsy C Wertheim, Denise J Roe, et al.
Magnetic Resonance Imaging|February 8, 2025
Concurrent water T<sub>2</sub> and fat fraction mapping of the breast using the radial gradient and spin echo (RADGRASE) pulse sequenceTomoe Hagio, Jean-Philippe Galons, Denise Roe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2016
Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive AgentsAllan Lipton, Matthew R Smith, Karim Fizazi, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2011
Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumorsDavid E Gerber, Alison T Stopeck, Lucas Wong, et al.
Breast Cancer Research and Treatment|September 16, 2022
Blood plasma derived extracellular vesicles (BEVs): particle purification liquid chromatography (PPLC) and proteomic analysis reveals BEVs as a potential minimally invasive tool for predicting response to breast cancer treatmentFolnetti A Alvarez, Hussein Kaddour, Yuan Lyu, et al.
Journal of Magnetic Resonance Imaging : JMRI|August 31, 2002
Radial fast spin-echo method for T2-weighted imaging and T2 mapping of the liverMaria I Altbach, Eric K Outwater, Theodore P Trouard, et al.
Clinical & Experimental Metastasis|June 14, 2012
The role of targeted therapy and biomarkers in breast cancer treatmentAlison T Stopeck, Ursa Brown-Glaberman, Hong Yuen Wong, et al.
Blood|June 27, 2012
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2015
The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone diseaseIngo J Diel, Jean-Jacques Body, Alison T Stopeck, et al.
Leukemia & Lymphoma|April 18, 2009
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Breast Cancer Research and Treatment|January 18, 2022
Sulindac Improves Stiffness and Quality of Life in Women Taking Aromatase Inhibitors for Breast CancerJessica A Martinez, Betsy C Wertheim, Denise J Roe, et al.
Magnetic Resonance Imaging|February 8, 2025
Concurrent water T<sub>2</sub> and fat fraction mapping of the breast using the radial gradient and spin echo (RADGRASE) pulse sequenceTomoe Hagio, Jean-Philippe Galons, Denise Roe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2016
Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive AgentsAllan Lipton, Matthew R Smith, Karim Fizazi, et al.
Pageof 5